Product Images Jaimiess

This description pertains to a medication called Jaimiess®, which consists of Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ethinyl Estradiol Tablets, USP. The tablets are presented in extended-cycle blister packs, with each containing 91 tablets. The pack includes 84 white to off-white tablets with 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, as well as 7 light peach tablets with 0.01 mg ethinyl estradiol. Each pack carries the NDC number 70700-206-93. The text provides detailed information on the composition and packaging of this contraceptive medication.*

This information provides data on the incidence of blood clots in Non-Pregnant and COC (contraceptive oral contraceptive) users, as well as during Pregnancy and the Postpartum period (up to 12 weeks post-birth). The data is presented as the number of women with a blood clot per 10,000 Women Years (WY) in the different groups. It also includes a model assumption for the rate of blood clots during pregnancy, based on the duration of pregnancy in reference studies.*

This text seems to contain a table showing data related to percentages and cycle days. The table provides information on bleeding and spotting percentages during different cycle days, with percentages ranging from 80% to 0%. It appears to encompass multiple cycles with varying sample sizes for each cycle, such as Cycle 1, Cycle 2, Cycle 3, and Cycle 4. The specific details and trends indicated by the percentages and cycle days appear to be structured for evaluation and analysis.*

This text provides information on relevant studies evaluating the risk of breast cancer with combined oral contraceptives (COC) use. It compares the risk between ever COC users and never COC users, as well as between current COC users and never-users. The studies mentioned include the NICHD Women's Care Study, French E3N cohortStudy, Shanghai Women's Health Study, The Nurses' Health Study I, and Oxford Family Planning Study. The text also includes data on risk estimates such as relative risk (RR), odds ratio (OR), and hazard ratio (HR) from these studies. The findings from these studies are used to assess the association between COC use and breast cancer risk.*

Levonorgestrel is a chemical compound with a molecular formula C21H28O2 and a molecular weight of 312.4 g/mol. It is commonly used as a progestin in hormonal contraceptives.*

Ethinyl Estradiol has a chemical formula of C20H24O2 and a molecular weight of 296.4. It is a synthetic estrogen used in many hormonal contraceptive formulations.*

This text provides information on different forms of birth control methods and their effectiveness in preventing pregnancies. It categorizes the frequency of pregnancies per 100 women in one year based on the method used, ranging from fewer than 1 pregnancy to 85 or more. The mentioned birth control methods include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal rings with hormones, condoms, diaphragm, no sex during the most fertile days of the monthly cycle, spermicide, withdrawal, and no birth control.*